Invention Grant
US07323466B2 Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity
失效
吗啉衍生物作为治疗肥胖症的5HT2C受体激动剂
- Patent Title: Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity
- Patent Title (中): 吗啉衍生物作为治疗肥胖症的5HT2C受体激动剂
-
Application No.: US11332103Application Date: 2006-01-13
-
Publication No.: US07323466B2Publication Date: 2008-01-29
- Inventor: Jonathan Mark Bentley , Claire Elizabeth Dawson , Wolfgang Guba , Paul Hebeisen , Nathaniel Monck , Robert Mark Pratt , Hans Richter , Stephan Roever , Vicki Ruston
- Applicant: Jonathan Mark Bentley , Claire Elizabeth Dawson , Wolfgang Guba , Paul Hebeisen , Nathaniel Monck , Robert Mark Pratt , Hans Richter , Stephan Roever , Vicki Ruston
- Applicant Address: US NJ Nutley GB Wokingham
- Assignee: Hoffman-La Roche Inc.,Vernalis Research Limited
- Current Assignee: Hoffman-La Roche Inc.,Vernalis Research Limited
- Current Assignee Address: US NJ Nutley GB Wokingham
- Agent George W. Johnston; Dennis P. Tramaloni; Brian C. Remy
- Priority: EP05100281 20050118
- Main IPC: A61K31/5375
- IPC: A61K31/5375 ; C07D265/30
Abstract:
The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments.
Public/Granted literature
- US20060178510A1 New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity Public/Granted day:2006-08-10
Information query
